首页> 外文OA文献 >Comparison of two granulation processes with the view to reduce manufacturing cost
【2h】

Comparison of two granulation processes with the view to reduce manufacturing cost

机译:比较两种造粒工艺以降低制造成本

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Aspen Pharmacare, one of the leading pharmaceutical manufacturers in South Africa has embarked on a programme of improving the production processes currently employed at their Port Elizabeth site. With the introduction of new technology at the site and the move towards globalization, it became imperative that Aspen remain competitive in the market. The product of interest in this research, Degoran Plus tablets, is one of the company’s leading brand sellers. Upon investigation, it became apparent that this product created opportunity for process improvement using the new technology. The manufacture of Degoran Plus entails granulation, compression and coating of the product. Most opportunity for improvement was possible in the granulation stage because of the laborious nature of the present process. Degoran Plus tablets had a history of analytical failures, especially with regard to the dissolution rate of the final product, as well as other quality related issues. The product was not considered to be a “through-runner”, which resulted in bad production output, due to continual repeats of not only analysis but also reworks in production. A strategic decision was taken to manufacture Degoran Plus using the Collette Gral granulator as the equipment offered superior mixing capability when compared to the Bear planetary granulator. It was assumed that the granulation process would result in more uniform distribution of the actives. Upon producing a better granule, a final product of superior quality would be attained. The validation protocol stipulates that three samples be taken and tested from the powder mix. Nine samples taken from granulated bulk are treated in the same manner. The validation protocol further stipulates that the first three batches manufactured utilise the new process, and tested according to the protocol. The results obtained from the analysis are evaluated statistically and a conclusion and recommendation were derived based on the evaluation.
机译:南非领先的制药商之一Aspen Pharmacare已着手改善其伊丽莎白港工厂目前采用的生产工艺的计划。随着现场新技术的引进和全球化的发展,Aspen在市场中保持竞争力变得势在必行。该研究中感兴趣的产品Degoran Plus平板电脑是该公司领先的品牌销售商之一。经调查,很明显,该产品为使用新技术的过程改进创造了机会。 Degoran Plus的制造需要对产品进行造粒,压缩和包衣。由于本方法的费力性质,在制粒阶段中最大的改进机会是可能的。 Degoran Plus片剂具有分析失败的历史,尤其是在最终产品的溶出率以及其他与质量相关的问题方面。该产品不被视为“直通车”,由于不仅仅分析而且在生产中进行了返工,还会导致产量不佳。做出了一项战略决策,即使用Collette Gral造粒机生产Degoran Plus,因为与Bear行星造粒机相比,该设备具有出色的混合能力。假定制粒过程将导致活性物质分布更均匀。当生产出更好的颗粒时,将获得高质量的最终产品。验证协议规定从粉末混合物中采集三个样品并进行测试。从颗粒状大块中取出的九个样品以相同的方式处理。验证协议还规定,制造的前三批产品应使用新工艺,并根据协议进行测试。对从分析中获得的结果进行统计评估,并根据评估结果得出结论和建议。

著录项

  • 作者

    Maclean Aldritt Allister;

  • 作者单位
  • 年度 2004
  • 总页数
  • 原文格式 PDF
  • 正文语种 English
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号